Vivek Subbiah: Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at The Sarah Cannon Research Institute, on LinkedIn:

“ICYMI from the latest issue—of American Association for Cancer Research Journal Cancer Discovery, pleased to share our paper “RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations”. Elegant bench to bedside precision medicine work from Relay Therapeutics and superb investigators from multiple sites.

Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic. So thankful for the patients and caregivers who were motivated to enroll on clinical trials. Thankful to all the trial staff.”

For the article click here.
Source: Vivek Subbiah/LinkedIn